Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
March 18, 2025
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being with us on this call for our Q4 and full-year 2024 earnings update and business review. Here with me today is my colleague Lisa Delfini, who serves as Chief Financial Officer of Trevi. Lisa and I will offer some remarks regarding the business and our financial results, and after that we'll be glad to take whatever questions you might have. Team Trevi executed strongly throughout 2024, producing three favorable data readouts within the last several months. Those were the Human Abuse Potential study, the Sample Size Re-Estimation, the CORAL study conducted in chronic cough patients with IPF, and the RIVER study involving patients with refractory chronic cough, or RCC. Altogether, these trials took place across 11 countries at roughly 75 different sites and involved multiple regulatory authorities. I feel great pride in our team and in the urgency and dedication they brought to conducting high quality trials. Every one of these trials generated data analyses that mattered a great deal for moving the clinical development plan of Haduvio forward. Let me walk through each of these key readouts briefly. In December, we reported positive results from our Human Abuse Potential, or HAP, study. Since nalbuphine is a centrally acting therapy, we had to update the package on drug likeability so it meets today's standards. As a reminder, injectable nalbuphine, which is indicated for severe pain, has existed for decades and remains unscheduled by the DEA. Nalbuphine falls within a drug class called mixed agonist antagonists, which were created so patients could obtain opioid efficacy while avoiding abuse potential. Two main reasons explain why nalbuphine has stayed unscheduled throughout all these years. First, given the drug's neo-antagonism effect, which may trigger withdrawal symptoms among people abusing opiate class drugs, those individuals neither prefer it nor seek it out. Second, the DEA's ongoing surveillance has not turned up any significant abuse issues. Both the 162 milligram and 81 milligram nalbuphine doses that were studied demonstrated statistically significant lower relative drug liking when compared with butorphanol. Given the effective doses we're observing in cough, the 162 milligram dose likely satisfies the requirement of 3x the marketed dose to qualify as super therapeutic. Nothing further needs to be done until we file our NDA, at which point we will submit an eight-factor plan that will incorporate this data. A final decision about whether scheduling changes will occur gets made upon approval by the FDA and DEA. We don't think we've demonstrated anything in our program that alters this drug's abusability risk profile, and we believe it will stay unscheduled, though that determination will ultimately come later. Turning to our clinical data: in December, we announced results from the sample size reestimation, or SSRE, analysis in our Phase 2b study in patients with IPF chronic cough. Before the trial began, we set up a planned statistical review of the highest dose group, 108 milligrams BID, timed for when half of the patients originally planned had finished the six weeks of treatment, in order to verify the assumptions behind our original powering. An unblinded statistician outside the company carried out this analysis. The sole thing we got back was whether we needed to adjust the sample size. We were quite happy that the SSRE confirmed the original sample size of 160 patients. What this favorable outcome basically does is validate the study's assumptions about effect size and expected variability, and it verified a conditional power of at least 80% or greater at the point when 50% were enrolled. That news was exciting for us and let us remain on the study's original timelines, finishing enrollment in February of this year. A bit of color on enrollment: our strongest months for enrollment were December and January, which I believe reflects enthusiasm about a possible treatment along with the substantial unmet need among these IPF patients who suffer from chronic cough. Right now a handful of patients are finishing their treatment, and we expect to report data from this trial in the second quarter of this year. This is our lead indication, and we're eager to obtain the data from this dose ranging study and move the development program forward. Then just last week, we announced results from our Phase 2a RIVER trial in patients with RCC, which includes those who have unexplained chronic cough. RCC is a debilitating disease affecting roughly 2 million to 3 million US patients, and no therapies are approved for it in the US. Importantly, many drugs have been studied in this condition and failed, all primarily peripherally acting agents, with only one drug still in late-stage development. Our hypothesis going into the RIVER study was that our central and peripheral mechanism might alter the outcome for patients suffering with this disease. The types of chronic cough we're studying are connected through hypersensitivity at the brain, which is why we think the central aspect of our mechanism matters. As reported last week, Haduvio hit the primary endpoint in the RIVER study, with a statistically significant reduction in 24 hour objective cough frequency, reaching a p-value of less than 0.0001 along with a 57% placebo adjusted change from baseline, and importantly it demonstrated the same strong effect across a range of cough counts, including patients with moderate or severe cough. So we're excited to advance development of Haduvio in RCC. As we've explained, with IPF as our lead indication and a specialty commercial sales model, we will develop Haduvio in RCC for patients who have failed prior therapy. We believe many patients aren't getting relief from the drugs currently used off-label, and even if a P2X3 antagonist is approved, such agents have only been shown to work in the most severe coughers, which represents less than a third of the market. Therefore, an important gap in care will persist for kidney cancer patients who no longer respond to any approved therapies. Shifting our attention toward those RCC individuals whose treatments have failed lets us concentrate on the group facing the greatest need, which enables us to zero in on one portion of the RCC population while keeping the premium pricing we have for our specialty IPF product. Turning to Trevi, the readouts have been coming rapidly. The upcoming event is the Phase 2b data for the CORAL study in patients with IPF who suffer from chronic cough. That readout, as I noted earlier, should arrive during the coming quarter. Our people have been working hard on plans for what comes next so that development of Haduvio can move ahead swiftly in IPF as well as in RCC. Regarding the IPF cough effort, the upcoming development milestones are as follows: once the data arrive and if the results are favorable, we will get ready for an End-of-Phase 2 gathering with the FDA, anticipated to take place no later than the close of 2025. During that gathering, we anticipate talking about the pivotal program we have in mind, the designs for our studies, the safety database that will be required, and whatever additional development studies are necessary to support an NDA submission. On the RCC side, we await the final datasets and are drafting a protocol for the following study; we intend to ask the FDA for a meeting so they can share their views on our program and the upcoming study. We plan to share additional RIVER data at the American Thoracic Society conference in May in San Francisco, and also at the European Respiratory Society Congress in September. One more thing: we intend to be very visible at ATS in San Francisco in mid-May. So should any of you be planning to go, please reach out to me. We intend to host a KOL panel that includes IPF specialists along with an RCC physician, aimed at investors. As is evident, we accomplished a great deal over this year, and Haduvio now stands as the first and only therapy in clinical development demonstrating a statistically significant decrease in chronic cough among patients with IPF and RCC. This establishes Haduvio as a first-in-class treatment for IPF and possibly best-in-class across chronic cough indications. We possess a targeted strategy for developing Haduvio in serious chronic cough conditions, one our team is capable of carrying out, and we believe it can create substantial value for the company along with its shareholders. I will hand things over to Lisa now so she can go through our financial results, and after that we will take any questions you might have.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon to all of you. You can find the complete financial results for the 3 and 12 months that ended December 31st, 2024 in the press release we issued before this call, as well as in our 10-K, which we filed with the SEC today after market close. For Q4 of 2024, we recorded a net loss of $11.4 million, versus a net loss of $7.8 million in the same quarter of 2023. R&D expenses came in at $9.3 million in Q4 of 2024, compared with $6.5 million in the comparable quarter of 2023. That rise was mainly driven by higher clinical trial costs tied to our Phase 2b CORAL trial, our Phase 2a RIVER trial, and our HAP study, along with greater personnel related expenses. G&A expenses grew to $2.9 million in Q4 of 2024, up from $2.4 million in the same period of 2023, largely because of higher stock-based compensation and personnel related expenses. As of December 31st, 2024, cash, cash equivalents, and marketable securities came to a total of $107.6 million. That figure includes a $50 million unwritten offering we closed in December following the two positive data readouts Jennifer talked about; this positioned us well so that we don't need to raise money off last week's positive RCC data. Our cash runway guidance into the second half of 2026 is unchanged and covers completing our ongoing Phase 2b CORAL trial for chronic cough in patients with IPF and, based on our current estimates, our next RCC trial. It does not cover funding for the next studies in IPF beyond some startup costs. In 2025, we anticipate cash burn net of interest income of roughly $12 million to $14 million per quarter in Q1 and Q2. Over the coming couple of quarters, we'll receive feedback from the FDA and plan the subsequent trial in RCC, assuming positive data trials in IPF and non-IPF ILDs. We'll provide additional cash burn guidance when we give guidance on the design and start date for these trials. Our current fully diluted shares outstanding stand at approximately 137 million, which includes approximately 10 million stock options outstanding; that wraps up our prepared remarks. I'll now hand the call back to the operator for Q&A.
Faisal Khurshid
analystHi there, good afternoon. I appreciate you taking my question. Now that enrollment for CORAL has wrapped up, I was hoping you could share a bit about the patients who were enrolled. More specifically, was there anything different between the first half of the study, prior to the sample size estimation, and the second half — that sort of bolus you mentioned in December and January, up until enrollment finished? Then I have one more question. Thanks.
Jennifer Good
executiveFaisal, thanks for asking. As you'll recall, we only received those results in December, and by then the study had reached nearly 75%, 80% enrolled. Because of that, no modifications were made — until we had those results, and even afterward, we didn't swap out any sites and there were no protocol changes. The study's overall statistics appear essentially unchanged. That's a key point here: aside from telling them we'd run the pre-planned analysis and that no upsize was needed, we did not share these results with the sites, since you don't want to alter the script they're following at the site. So no — we've taken great care to ensure there were no changes across the second half of this population.
Faisal Khurshid
analystUnderstood, that helps. And I believe earlier you made a remark or two about the rate of discontinuation you had been observing in the earlier portion of CORAL — could you speak to that at this point, given that dosing for the study is nearly finished, and describe how it has behaved over the latter half?
Jennifer Good
executiveRoughly 60 minutes ago, Jim told me we remain in single digits. So in fact it held extremely steady for the entire study. That figure is the total; only the total blinded is visible to us. Therefore I clearly cannot tell who received drug versus placebo, but we remained in single digits, and it held extremely steady throughout the study.
Faisal Khurshid
analystGreat, thanks. I can't wait to see those figures.
Jennifer Good
executiveAbsolutely, appreciate it, Faisal.
Mayank Mamtani
analystHello, good afternoon, everyone. We appreciate you answering our questions, and congratulations on the solid performance lately. Could you share some thoughts regarding what you expect for placebo response in the Phase 2 trial of IPF chronic cough? Also, would you be able to verify the two-week placebo run-in that you mentioned, and, sorry, this is a multi-part question, in what ways might your baseline cough count be different from the one in CANAL?
Jennifer Good
executiveSure. To start, regarding the two-week placebo run-in, that is actually not a two-week placebo run-in; it is a two-week titration period, and it will be included in every study we conduct. So I want to make that clear. Placebo has not been a major issue in IPF studies so far. It has behaved quite well, so we saw no reason to include any type of placebo run-in. For the powering assumptions regarding placebo, we had assumed a 66% drug effect and 30% placebo, giving a 36% placebo-adjusted change. As you are aware, our SSRE confirmed that we are at least at that effect size or larger, so I believe we were fairly conservative about our placebo effect. We have generally observed across earlier IPF cost studies, of which there are not many, that the placebo effect has ranged from roughly 15% to 23%, so I think we have been quite conservative there. Now regarding baseline cough counts, we are not — our medical monitor is reviewing that, but I am definitely not reviewing that at my level, and I do not think Jim is either. Therefore, I have no comments about what baseline cough counts look like. I do know that our inclusion criteria for how you get in, and sort of the minimum baseline costs that are required for a VAS score, did not change. So, I would assume we should be approximately in the same range.
Mayank Mamtani
analystUnderstood. Thanks. Could I perhaps ask regarding the RIVER RCC data — now that it's available and KOLs are reviewing it, how do you envision the RCC patient population being divided between P2X3 and Haduvio, supposing both reach the market within roughly the coming three-to-four-year window? Thanks once more for taking the questions.
Jennifer Good
executiveYes. Thank you, Mayank. As we've stated from a commercial standpoint, we're focused on treating essentially patients who are treatment failures. At present, they're all getting used, all being tried on off-label agents that truly don't perform that well. Consequently, every patient who lands in these trials has already gone through roughly that tier of treatments. Should the P2X3 reach the market, and Glaxo succeeds — which I hope happens, for the sake of patients — I believe we'll aim to — you can attempt your P2X3 first, but should you fail it, you'll then receive our Haduvio therapy. That makes it second or third-line therapy, contingent on what gets approved. I believe substantial unmet need remains. As you're likely aware, the P2X3 has only succeeded among severe coughers, and even there it failed to demonstrate efficacy in 40% of them; thus plenty of individuals continue seeking treatment across this moderate and severe, somewhat arbitrary, boundary. I think those genuinely pursuing therapy can't obtain treatment that helps them. I think they'll ultimately wind up trying our Haduvio.
Mayank Mamtani
analystThank you.
Jennifer Good
executiveThank you.
Annabel Samimy
analystHi. I appreciate you fielding my questions. Now that roughly 10 days have passed since the data came out, I have a few more inquiries about it. Is there anything you can tell us about the efficacy that appeared to plateau at the 54 milligram dose? And was that consistent with what you observed in the earlier IPF trial — did you see a plateau there too? And might you still be looking at possibly using lower dosing in the CORAL studies? I realize you need to wait and see, but it sounds like if you had any plateauing in CANAL, that could suggest you might potentially consider lower doses there? I want to ask this with the adverse events in mind, and how we might get better at handling them — did those AEs come up right when treatment started, or did they show up later as the dose was increased? That's my first question, and I know it's a long one.
Jennifer Good
executiveYep. No, I'm with you — these are all fair questions. Annabel, my understanding is that nothing new has come in past what we already had from the top-line readout. Honestly, it's strange to think that was 10 days ago; it feels more like two days, everything's been a blur. That said, what I'd point to is the contrast with CANAL, which was our first IPF trial — there, we didn't have VitaloJAK measurements taken at every dose level. We couldn't use objective measures — we depended on outcomes the patients told us about. That curve looked comparable, yet it appeared to demonstrate activity on the pro all the way up to 108 milligrams. And in this particular trial, as you point out, the data fairly plainly indicate that the range where the drug works seems to sit between 27 and 54. As for CORAL in IPF, that parallel arm design should tell us a great deal, I believe, regarding dosing. So my strong sense is — and Jim and I have discussed this too — that for RCC, the 108 milligram level probably won't be necessary. We'll land at the lower portion of that range, which is always a plus when it comes to the side effect question you were raising. There's the option of going up more gradually, or having someone take it just once in the evening — a single nightly dose for a period, which helps patients acclimate to the medication. That approach simply provides far greater room to maneuver, since you aren't rushing to push patients toward a stronger effective dose right away. So, to answer that, additional data isn't available yet. Once it is, we'll present some of those details. I suspect a portion of this will be part of what I discuss at ATS, though as of now this is the extent of our knowledge. The CMC group is reviewing the dosing levels and considering if a dose below 27 might actually be required. So we're also making plans in that direction.
Annabel Samimy
analystUnderstood. Then, very briefly regarding the RCC, the upcoming study. Is that one also still going to enroll an all-comers refractory group? Given that you're kind of aiming this at third-line use following P2X3s, are you altering the inclusion criteria at all? I suppose you can't truly place it that way within a trial, but is there anything regarding the inclusion criteria or the populations you might be evaluating in the next study?
Jennifer Good
executiveNo. In our inclusion criteria, it will be very close to what we recently completed. There has to be some minimum cough level. Everyone has converged on 8 to 10 coughs, since we aren't attempting to target that mild intermittent group. Beyond that, we no longer separate moderate from severe. The cough field doesn't operate that way. It's kind of an arbitrary construct invented for clinical trials; so we'll simply proceed, which I believe provides us many advantages in recruiting and flexibility. So I think that will be very useful. And your question had a second part, I apologize, which I've forgotten.
Annabel Samimy
analystNope, that's — you've basically hit all of it. That's great. Thanks.
Jennifer Good
executiveAll right. There was one more thing I meant to mention that I forgot. Anyway, thank you, Annabel.
Annabel Samimy
analystAll right. Many thanks.
Leland Gershell
analystHi there, good afternoon, Jennifer, and hello to the whole team. Appreciate you fielding this. My question is about timelines. When we last spoke, that was ahead of the RIVER readout, and my understanding is that beyond the efficacy results, you'd also require longer-term exposure information to complete the NDA submission, and that would presumably affect when an initial approval could come. So I'm curious: if you're running RCC as a Phase 3, and you've also got what I'd count as two Phase 3 trials for IPF cost, might that speed up your path to market, given that you could wind up with extra safety exposure data from patients enrolled in that later-stage RCC trial? Thank you.
Jennifer Good
executiveYes, Leland, that's a fair question. At this point, we have not run any open-label extension data. Starting now, we need to begin doing that. As you're aware, our regulatory approach calls for the IPF study to serve as our first NDA, as currently planned. That's the NDA where we'll sit down with the FDA and work out what sort of safety database exposures they're going to require. RCC would come as an SNDA. It's therefore a follow-on, and we'll be able to take advantage of all the exposure data generated around IPF, and within that strategy it amounts to just one pivotal study. So these are exactly the sorts of matters we need to really work through together with the regulatory authorities. And as you also know, we hold a substantial amount of safety data from our earlier clinical programs, and that covers both 6 months and 12 month safety data. How all of that comes together is something we'll have to sort through, because my sense is that with this effect size, our actual efficacy trials won't have to be very large. So what will likely drive things is the safety database more than anything else.
Leland Gershell
analystOkay, I appreciate the additional detail.
Jennifer Good
executiveI also wanted to circle back, Annabel — I recalled what you'd asked secondly, regarding patients for whom treatment hasn't worked; to wrap up that thought, every one of these individuals has now experienced failure. In the upcoming trial, I believe it will simply involve recording that they have attempted alternative options and did not respond to a different cough-suppressing medication. That will then be incorporated into our study documents, and from a development standpoint, we will meet that obligation. Let's take the next question.
Serge Belanger
analystHello, and good afternoon. To start, I'd like an update on the respiratory physiology study — is it still progressing as planned and expected to wrap up during the back half of the year? Also, has it been adjusted in light of the latest information coming out of RCC?
Jennifer Good
executiveThat's a fair question, Serge. That trial is currently screening patients and is moving forward. There have been, I'd call them, operational and logistical matters that needed to be sorted through. Nobody has ever run this kind of study before. So once again, this is just the usual sort of Phase 1 situation. We've got 2 solid sites and have managed to get through those issues. Jim has returned to thinking about whether the 108 milligram dose is actually needed for this trial, so that discussion is currently in progress. Previously we had been dosing all the way up through 108, though I believe some people are now wondering if we might end up not reaching that dose, or the study, after all. So it continues, and we remain on schedule to have it ready for our End-of-Phase 2 meeting, where we'll present our data and talk over our next steps with the agency.
Serge Belanger
analystThanks.
Jennifer Good
executiveThank you, Serge.
Ryan Deschner
analystHi, thanks for taking the question. When the 3Q IPF chronic cough data comes out, which exploratory measures should we expect to see — particularly EXACT question 2 or sleep cough frequency? Then I have one more.
Jennifer Good
executiveSure, Ryan, that's a fair question, and honestly I don't know the specifics. What I can say is that in the topline we'll clearly have the primary endpoint plus a number of the important secondary ones. EXACT-2 is certainly going to be included, since it's among the key secondary studies in the endpoint, and I believe CS-VAS as well. Past that, though, I'm not sure whether any of the remaining secondary endpoints will be reported.
Ryan Deschner
analystAll right. Then when we think about a later-phase RCC trial, which kinds of stratification—say, how often someone coughs—might you factor in, given everything RIVER has taught us up to now?
Jennifer Good
executiveRight. My colleagues here are gesturing at me as well. It sounds like you mentioned Q3 for the data, but it's Q2, so we're on the same page. Right, as we move forward in RCC, there won't be any stratification; across moderate and severe cases, the effect looked almost identical. Of course, we'll review each patient's data individually, but the signal was robust; and given how our mechanism works, that matched our expectations. That's also what IPF cough showed us; therefore, we have no plans to stratify whatsoever between moderate and severe patients.
Ryan Deschner
analystUnderstood — we're eager for the second-quarter results.
Jennifer Good
executiveAbsolutely, appreciate it, Ryan.
Brandon Folkes
analystHello. I appreciate you fielding my questions. Perhaps, from my side, I just want to dig a bit deeper into that placebo rate. Is there any kind of scientific explanation for why placebo rates in IPF might come out differently compared to RCC? Clearly, with RCC data, we've heard about the powering that you brought up before. Is it simply a matter of how those trials were structured, or is there some scientific logic we ought to keep in mind when that data comes out and we're examining the placebo-adjusted figures? Thank you.
Jennifer Good
executiveRight, this question has come my way, since the placebo rate in CANAL IPF was in fact somewhat greater than in RCC, and that seems counterintuitive; typically these crossover studies stay fairly tight. So placebo typically doesn't show up until you get to the parallel arm design. My guess is that it's due to the RCC studies — everyone runs those across roughly the same 10 to 15 centers, high-end cost centers, truly top-tier thought leaders in this area. IPF is somewhat more spread out among ordinary IPF centers that are conducting plenty of trials. So there isn't — I lack a solid scientific explanation. And Jim was asked about this last week, and we didn't have a solid answer either. I believe the positive side is that these generally fall within what we had anticipated. The RCC study was very tight, but we will definitely account for greater placebo rates in the parallel arm for the next study.
Brandon Folkes
analystAlright, I appreciate you answering my questions, and congratulations on the encouraging results you've reported recently.
Jennifer Good
executiveThank you, Brandon.
Christian Cubides
analystHello, Christian here. I'm filling in for Kaveri at the moment, so congratulations on the RCC data you presented not long ago. And moving forward, I suppose, when it comes to indications, could you share which secondary endpoints you believe will be the most important for boosting Haduvio prescriptions and reducing pushback from payers?
Jennifer Good
executiveYeah, that's a fair question. There's some effort underway regarding secondary endpoints tied to patients, I'd say. The initial consideration, I think, is ensuring the FDA is satisfied that your key secondary measures connect to your primary endpoint of objective cost. That appears to be focusing on cost severity, and that's not exactly equivalent to cost frequency. Once you're dealing with payers and similar matters, things such as quality-of-life metrics for the patient carry weight. Our commercial team is engaged in these upcoming studies and in deciding which metrics get included as secondary endpoints, but the result will be a blend of the severity scales plus a number of the quality-of-life metrics too.
Christian Cubides
analystGot it. Thank you.
Jennifer Good
executiveThank you, Christian.
Jennifer Good
executiveThanks. We’re eager for the 2b CORAL trial data coming next quarter, and we’re glad you’re on today’s call. Lisa and I will be around afterward if you have any follow-up questions.
Operator
operatorThat brings us to the end of this call. We appreciate you joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.